奥贝胆酸图片及药品说明

Generic name: obeticholic acid

Product name: Obetix

All names: Obeticholic acid,Obeticholic acid,Obetix,Ocaliva

Obeticholic acid is effective against liver cirrhosis and fatty liver. Bican is the first generic drug to be launched, and the price is less than 5% of that in the United States.

(Obeticholic acid) is the only drug approved by the US FDA for the treatment of primary biliary cirrhosis (PBC) in the past 20 years. It can significantly improve the biochemical indicators of PBC patients who have poor response or intolerance to ursodeoxycholic acid (UDCA) treatment, delay disease progression, and improve survival rates.

PBC, also known as primary biliary cholangitis, is a chronic progressive autoimmune liver disease that can lead to cirrhosis or liver scarring. As cirrhosis progresses, the amount of scar tissue in the liver increases, liver failure occurs, and a liver transplant is required. PBC medication cycle is long and may even require lifelong medication.

Obeticholic acid has been proven effective in the treatment of non-alcoholic steatohepatitis (NASH), and the US FDA has granted it Breakthrough Therapy designation.

NASH is a severe, progressive non-alcoholic fatty liver disease caused by fat accumulation, often accompanied by liver inflammation, hepatocellular scarring and liver damage, causing liver fibrosis and cirrhosis, eventually leading to liver cancer or liver failure.

The estimated adult incidence of NASH is at least 3% to 5%, and the median survival of patients is only about 5 years. Over the next 10 years, NASH is expected to become the leading cause of liver transplantation.

Obetix indications:

Obeticholic acid combined with ursodeoxycholic acid (UDCA) is indicated for adult patients with primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) who have an inadequate response to UDCA, or as monotherapy for adults with primary biliary cholangitis who are intolerant to UDCA.

Obetix usage and dosage:

For oral tablets, the initial recommended dose is 5 mg once daily.

Based on clinical response, treatment is gradually titrated to 10 mg (once daily) over 6 months.

Use of Obetix special groups:

Not suitable for patients with complete intestinal obstruction.